Cyclic peptides can look manageable at the bench and become expensive to manufacture at scale. The chemistry that delivers 50 milligrams for a screening campaign is not always the chemistry that delivers kilograms at an acceptable cost.
Where the difficulty sits
In solution-phase cyclisation, the two ends of one peptide chain must find each other. They compete with intermolecular coupling, where separate chains join instead and form oligomers.
Running the reaction at high dilution favours ring closure. It also raises solvent demand and the reactor volume needed for a given amount of product. A step that is routine in a flask can require a large vessel and a significant solvent charge at scale.
Depending on sequence and chemistry, the impurities may include cyclic dimers, epimers (molecules with one amino acid in the mirror-image form) or incorrectly paired disulfides. Some of these are close enough to the target molecule to be difficult to separate, which pushes work onto purification and reduces usable yield.
The questions that decide cost at scale
At commercial scale, the chemistry turns into four practical questions:
- How much material can the process deliver per batch?
- What solvent and purification capacity will it require?
- How will the critical impurities be controlled?
- Can the starting-material strategy be justified under ICH Q11?
That last question matters more than it may appear. ICH Q11 governs where GMP control begins in a synthetic route. If a regulator does not accept a proposed starting material, more of the route falls under GMP, which changes both cost and the choice of manufacturer.
Why the timing matters
A low-yielding cyclisation or a complex oxidation sequence has consequences well beyond that one reaction. It sets batch size, solvent volumes, purification load and the number of campaigns needed to supply a trial.
These effects usually become visible after candidate selection, when the route is harder to change. Early route scouting and a preliminary cost-of-goods assessment should therefore inform candidate selection rather than follow it.
The same applies to manufacturer engagement
The question is not simply who makes peptides. It is who can support the specific chemistry, scale and development stage your project requires. Those three things rarely sit in the same place.
Three European and Japanese companies show how different the answers can be:
PeptiStar (Japan). A GMP CDMO for peptide and oligonucleotide APIs, based in Settsu, Osaka. It runs from research scale through to commercial production, with some of the largest filter reactors and lyophilisers in Japan.
BCN Peptides (Spain). Focused on cGMP manufacture of bioactive peptides using solid-phase synthesis, producing multi-kilo batches from R&D through clinical trial supply to bulk commercial quantities.
Genepep (France). A CRO in Montpellier specialising in peptide design, synthesis and optimisation at the discovery and early-development stage. Its work is non-GMP, so it fits route scouting rather than clinical or commercial supply.
The contrast is the point. A company that can solve a difficult cyclisation on paper may not be the company that runs it under GMP at scale. Check each supplier’s capabilities, scale and regulatory scope against the stage your project has reached.
In summary
Cyclic peptide routes are easier to change before candidate selection than after it. Scout the route early, estimate the cost of goods while more than one option is open, and match each potential manufacturer to the stage and scale you actually need. Some will already be on your list. Others may be worth considering.
CDMO Hub helps sponsors broaden the search beyond the usual shortlist. Use cdmohub.ai to compare peptide manufacturers by capability, scale and regulatory scope.
The PDF edition
Get this briefing as a designed 2-page PDF
You have just read the whole thing. The PDF is the same analysis, typeset for circulation — the version to forward to your CMC or process chemistry lead or drop into a partner-selection pack.
- 2 pages, print-ready, with the full source list
- The four questions that decide cost at scale plus three manufacturer examples
- Optional: future issues, roughly monthly